Can a chromium supplement tame blood sugar before problems start?

NCT ID NCT07711587

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This pilot study tests whether a daily dietary supplement called Diaplex can improve how the body handles blood sugar in healthy adults aged 30 to 65 who have mildly elevated glucose levels. Over 16 weeks, participants receive either Diaplex or a placebo, and researchers measure insulin sensitivity and blood sugar patterns using continuous glucose monitors. The goal is to gather preliminary data on safety and effectiveness to guide larger future studies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a dietary supplement called Diaplex, which contains chromium and other ingredients
What this could lead to
If it works, this could point toward a natural supplement for managing early blood sugar elevations in otherwise healthy people.
What could go wrong
This is a small, early pilot study with only 40 participants, so results may not be conclusive or apply to everyone. The supplement may show no benefit over placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria • Adults 30-65 years old with elevated average blood glucose levels (100-125 mg/dL), confirmed at screening (HbA1c 5.7-6.4%) • BMI 18.5-29.9 kg/m² (normal to overweight) • Generally healthy individuals with no metabolic or endocrine disorders besides elevated blood glucose levels, meaning no metabolic syndrome, insulin resistance diagnosis, dyslipidemia diagnosis requiring treatment, thyroid disorders, etc. • Stable weight for the past 3 months (±5%) • Sedentary or lightly active baseline lifestyle (Light activity ≤3 times/week (e.g., walking, yoga, casual biking) • Willingness to maintain usual diet, activity, and sleep patterns for 16 weeks • Able and willing to wear a CGM for the final 10-14 days • Willing to complete 3-day dietary recalls, sleep and activity logs • Not taking or willing to stop taking supplements containing chromium, vitamin A, vitamin B6, iodine, and niacin • Able and willing to provide informed consent and complete all study visits 6 Exclusion Criteria • Any diagnosed metabolic/endocrine disorder, other than elevated blood glucose levels, such as metabolic syndrome, insulin resistance diagnosis, clinically significant dyslipidemia, thyroid dysfunction or use of thyroid medication, or obesity-related endocrine dysfunction • Medications and supplements use of glucose-lowering medications within the past 3 months, including use of weight-loss drugs or metabolic agents, such asGLP-1 RAs (Ozempic, Wegovy, Rybelsus, Trulicity, Victoza, Saxenda) or GIP/GLP-1 RAas (Mounjaro, Zepbound) • Use of supplements within the last 30 days containing chromium, vitamin A, vitamin B6, niacin, iodine • Unwilling to discontinue prohibited supplements • Health Conditions \& safety such as elevated ALT/AST more than 2× the upper limit or known chronic liver disease or diagnosed renal impairment (eGFR \<45 mL/min/1.73 m²), uncontrolled hypertension (\>160/100 mmHg) • Pregnant, breastfeeding, or planning pregnancy • Allergy or sensitivity to study ingredients or CGM adhesives • Lifestyle and compliance (\>30 minutes/day of intense physical activity (active adults or athletes)) • Participation in another investigational trial in the past 30 days • Any condition that may interfere with participation or data quality (per investigator guidance)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Elevated blood glucose are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hyperglycemia Insulin Resistance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.